{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "net-sales", "type": "clause", "offset": [50, 59]}, {"key": "products-sold", "type": "clause", "offset": [94, 107]}, {"key": "each-calendar-year", "type": "definition", "offset": [170, 188]}, {"key": "base-volume", "type": "definition", "offset": [258, 269]}, {"key": "the-excess", "type": "clause", "offset": [354, 364]}], "size": 6, "snippet": "for a particular period means that portion of the Net Sales (as defined below) of each of the Products sold by MEC or any of its Affiliates to KO/MEC Distributors during each calendar year (prorated for any period less than a calendar year) that exceeds the Base Volume during such calendar year (prorated for any period less than a calendar year) (i.e. the excess only).", "samples": [{"hash": "9S3e1yqAo6P", "uri": "/contracts/9S3e1yqAo6P#incremental-net-sales", "label": "Distribution Coordination Agreement", "score": 31.340862423, "published": true}, {"hash": "kzZhUGXfXJq", "uri": "/contracts/kzZhUGXfXJq#incremental-net-sales", "label": "Distribution Coordination Agreement (Monster Beverage Corp)", "score": 26.6043805613, "published": true}, {"hash": "invzSmu2doX", "uri": "/contracts/invzSmu2doX#incremental-net-sales", "label": "Transaction Agreement (New Laser Corp)", "score": 26.3360711841, "published": true}], "hash": "65b0545bf7e56a42a5f3505ccc69ac23", "id": 1}, {"snippet_links": [{"key": "genuine-parts", "type": "definition", "offset": [36, 49]}], "size": 3, "snippet": "means sales minus returns of Toyota Genuine Parts to Customers.", "samples": [{"hash": "18ZmjnlnIzB", "uri": "/contracts/18ZmjnlnIzB#incremental-net-sales", "label": "Dealer Participation Agreement", "score": 26.9780971937, "published": true}, {"hash": "b1cPzMDbjQn", "uri": "/contracts/b1cPzMDbjQn#incremental-net-sales", "label": "Dealer Participation Agreement", "score": 25.4832306639, "published": true}, {"hash": "5vRGgndC8Qv", "uri": "/contracts/5vRGgndC8Qv#incremental-net-sales", "label": "Dealer Participation Agreement", "score": 25.4832306639, "published": true}], "hash": "4e94711972542d7146a335bf584fba87", "id": 2}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "contract-year", "type": "clause", "offset": [43, 56]}, {"key": "in-the-territory", "type": "clause", "offset": [81, 97]}], "size": 3, "snippet": "means, with respect to any Product and any Contract Year, XXXXX for such Product in the Territory for such Contract Year XXXXX:\n(a) XXXXX", "samples": [{"hash": "ijSyMK41Jbj", "uri": "/contracts/ijSyMK41Jbj#incremental-net-sales", "label": "Copromotion Agreement (Impax Laboratories Inc)", "score": 21.0, "published": true}, {"hash": "e14BOJS7cT1", "uri": "/contracts/e14BOJS7cT1#incremental-net-sales", "label": "Copromotion Agreement (Impax Laboratories Inc)", "score": 21.0, "published": true}, {"hash": "8o7JmwReP36", "uri": "/contracts/8o7JmwReP36#incremental-net-sales", "label": "Copromotion Agreement (Impax Laboratories Inc)", "score": 21.0, "published": true}], "hash": "74b9a75927c0ffe58a4a45e0519544fd", "id": 3}, {"snippet_links": [{"key": "with-respect-to-an", "type": "clause", "offset": [11, 29]}, {"key": "section-44", "type": "clause", "offset": [106, 117]}, {"key": "pursuant-to-a", "type": "definition", "offset": [224, 237]}, {"key": "request-for-confidential-treatment", "type": "clause", "offset": [238, 272]}, {"key": "filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [304, 364]}, {"key": "alliance-program", "type": "definition", "offset": [422, 438]}, {"key": "competing-product", "type": "clause", "offset": [458, 475]}, {"key": "all-sales", "type": "clause", "offset": [477, 486]}, {"key": "alliance-products", "type": "definition", "offset": [547, 564]}, {"key": "at-the-time", "type": "clause", "offset": [587, 598]}, {"key": "for-purposes-of-this-section", "type": "clause", "offset": [662, 690]}, {"key": "existing-customer", "type": "definition", "offset": [753, 770]}, {"key": "resulting-from", "type": "definition", "offset": [939, 953]}, {"key": "volume-increases", "type": "clause", "offset": [963, 979]}], "size": 3, "snippet": "means:\n(a) With respect to an Alliance Product Commercialized after rejection of the NPCD as described in Section 4.4 (a) (\u201cNew Alliance Product\u201d), Incremental Net Sales means: [***] indicates material that has been omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the Securities and Exchange Commission.\n(i) where the New Alliance Product, if sold outside the Alliance Program, would have been a Competing Product, all sales of such New Alliance Product less any Cannibalized Sales of Alliance Products which were being sold at the time such New Alliance Product was first sold. \u201cCannibalized Sales\u201d for purposes of this Section 1.49(a)(i) means sales resulting solely from the switch by an existing customer from an existing Alliance Product to the New Alliance Product where both such Alliance Products have the same Clinical Intent, but does not include any increased sales resulting from price or volume increases attributable to the switch by an existing customer to the New Alliance Product; or", "samples": [{"hash": "7FM6asCp909", "uri": "/contracts/7FM6asCp909#incremental-net-sales", "label": "Strategic Alliance Agreement (Celera CORP)", "score": 21.0, "published": true}, {"hash": "6rMe90CZwwl", "uri": "/contracts/6rMe90CZwwl#incremental-net-sales", "label": "Strategic Alliance Agreement (Celera CORP)", "score": 21.0, "published": true}, {"hash": "5o6Ev8xCLO1", "uri": "/contracts/5o6Ev8xCLO1#incremental-net-sales", "label": "Strategic Alliance Agreement (Celera CORP)", "score": 21.0, "published": true}], "hash": "e6088753c13e7d09d1539d2fdb4ef874", "id": 4}, {"snippet_links": [{"key": "the-net", "type": "clause", "offset": [46, 53]}, {"key": "products-sold", "type": "clause", "offset": [94, 107]}, {"key": "each-calendar-year", "type": "definition", "offset": [170, 188]}, {"key": "base-volume", "type": "definition", "offset": [258, 269]}, {"key": "the-excess", "type": "clause", "offset": [355, 365]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [373, 391]}, {"key": "the-applicable", "type": "clause", "offset": [404, 418]}, {"key": "prior-to-the-effective-date", "type": "clause", "offset": [481, 508]}, {"key": "from-and-after-the-effective-date", "type": "clause", "offset": [596, 629]}, {"key": "this-exhibit", "type": "definition", "offset": [701, 713]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [724, 796]}, {"key": "pursuant-to-a", "type": "definition", "offset": [797, 810]}, {"key": "request-for-confidential-treatment", "type": "clause", "offset": [811, 845]}], "size": 3, "snippet": "for a particular period means that portion of the Net Sales (as defined below) of each of the Products sold by \u2587\u2587\u2587 or any of its Affiliates to KO/\u2587\u2587\u2587 Distributors during each calendar year (prorated for any period less than a calendar year) that exceeds the Base Volume during such calendar year (prorated for any period less than a calendar year) (i.e., the excess only). For the purpose of determining the applicable Incremental Net Sales, any Net Sales to Coca-Cola Enterprises prior to the Effective Date shall not be included in the Base Volume (i.e., all Net Sales to Coca-Cola Enterprises from and after the Effective Date shall be included in Incremental Net Sales). *** Indicates portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.", "samples": [{"hash": "invzSmu2doX", "uri": "/contracts/invzSmu2doX#incremental-net-sales", "label": "Transaction Agreement (New Laser Corp)", "score": 26.3360711841, "published": true}, {"hash": "bZN8zz4lRGT", "uri": "/contracts/bZN8zz4lRGT#incremental-net-sales", "label": "Transaction Agreement (New Laser Corp)", "score": 26.3004791239, "published": true}], "hash": "ef9daec381fd72b1fe05f70b037a6547", "id": 5}, {"snippet_links": [], "size": 2, "snippet": "shall have the meaning assigned to such term in Section 5.3.5.", "samples": [{"hash": "4oRhooXkkq", "uri": "/contracts/4oRhooXkkq#incremental-net-sales", "label": "Collaboration and License Agreement (Egalet Corp)", "score": 26.2019164956, "published": true}, {"hash": "lYgizI8sUKJ", "uri": "/contracts/lYgizI8sUKJ#incremental-net-sales", "label": "Collaboration and License Agreement (Acura Pharmaceuticals, Inc)", "score": 26.1635865845, "published": true}], "hash": "41885da227d60c7c11df3511aa2ba95f", "id": 6}, {"snippet_links": [{"key": "the-net", "type": "clause", "offset": [26, 33]}, {"key": "the-product", "type": "clause", "offset": [43, 54]}, {"key": "net-sales-amount", "type": "definition", "offset": [100, 116]}], "size": 2, "snippet": "means the amount by which the Net Sales of the Product for a particular period exceeds the Baseline Net Sales Amount for such period.", "samples": [{"hash": "cfySEQOgq97", "uri": "/contracts/cfySEQOgq97#incremental-net-sales", "label": "Co Promotion Agreement (Auxilium Pharmaceuticals Inc)", "score": 23.8364134155, "published": true}, {"hash": "4XLjzs3Qqcm", "uri": "/contracts/4XLjzs3Qqcm#incremental-net-sales", "label": "Co Promotion Agreement (Auxilium Pharmaceuticals Inc)", "score": 23.5790554415, "published": true}], "hash": "095860b1afdbf8821200d21bc0a668fd", "id": 7}, {"snippet_links": [{"key": "gross-margin", "type": "definition", "offset": [16, 28]}, {"key": "receipt-of", "type": "clause", "offset": [58, 68]}, {"key": "the-gross", "type": "clause", "offset": [69, 78]}, {"key": "margin-payment", "type": "clause", "offset": [79, 93]}, {"key": "in-lieu-of", "type": "clause", "offset": [143, 153]}, {"key": "royalty-payments", "type": "clause", "offset": [158, 174]}, {"key": "payable-to", "type": "definition", "offset": [185, 195]}, {"key": "the-agreement", "type": "clause", "offset": [208, 221]}, {"key": "based-on", "type": "clause", "offset": [233, 241]}, {"key": "resulting-from", "type": "definition", "offset": [264, 278]}, {"key": "health-care-providers", "type": "definition", "offset": [308, 329]}, {"key": "contained-in", "type": "definition", "offset": [330, 342]}, {"key": "pursuant-to-section", "type": "clause", "offset": [375, 394]}, {"key": "in-respect-of", "type": "clause", "offset": [425, 438]}, {"key": "calendar-quarter", "type": "definition", "offset": [441, 457]}, {"key": "within-thirty", "type": "clause", "offset": [515, 528]}, {"key": "detail-report", "type": "definition", "offset": [588, 601]}, {"key": "for-clarity", "type": "clause", "offset": [670, 681]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [917, 946]}, {"key": "responsible-for", "type": "clause", "offset": [964, 979]}, {"key": "distribution-activities", "type": "definition", "offset": [984, 1007]}, {"key": "relating-to", "type": "definition", "offset": [1008, 1019]}, {"key": "the-product", "type": "clause", "offset": [1020, 1031]}], "size": 2, "snippet": "means [*****]. \u201cGross Margin\u201d shall mean [*****]. Acura\u2019s receipt of the Gross Margin payment described above (\u201cCo-Promotion Payment\u201d) will be in lieu of the royalty payments otherwise payable to Acura under the Agreement calculated based on Incremental Net Sales resulting from prescriptions written by the health care providers contained in Acura\u2019s list provided to Egalet pursuant to Section 5.3.13. Co-Promotion Payments in respect of a Calendar Quarter shall be paid within forty-five (45) days; (or if later, within thirty (30) days following Acura\u2019s provision to Egalet of Acura\u2019s Detail report described in Section 5.3.9) after the end of such Calendar Quarter. For clarity, Acura will not be entitled to a Co-Promotion Payment in respect of any prescriptions written by health care providers that are not Acura\u2019s list provided to Egalet pursuant to Section 5.3.13, even if Acura has Detailed such providers. Notwithstanding the foregoing, Egalet shall be responsible for all distribution activities relating to the Product.", "samples": [{"hash": "4oRhooXkkq", "uri": "/contracts/4oRhooXkkq#incremental-net-sales", "label": "Collaboration and License Agreement (Egalet Corp)", "score": 26.2019164956, "published": true}, {"hash": "lYgizI8sUKJ", "uri": "/contracts/lYgizI8sUKJ#incremental-net-sales", "label": "Collaboration and License Agreement (Acura Pharmaceuticals, Inc)", "score": 26.1635865845, "published": true}], "hash": "9d393e7354dd4684009859599fa6c891", "id": 8}, {"snippet_links": [{"key": "net-sales", "type": "clause", "offset": [6, 15]}, {"key": "in-the-territory", "type": "clause", "offset": [16, 32]}], "size": 2, "snippet": "means Net Sales in the Territory of a Product that is greater of (a) *** or (b) ***.", "samples": [{"hash": "9VCVWpOB55t", "uri": "/contracts/9VCVWpOB55t#incremental-net-sales", "label": "Joint Venture Agreement (Senesco Technologies Inc)", "score": 23.1190965092, "published": true}], "hash": "c5a3b24522ab6f17f58d06f3d5cb0313", "id": 9}, {"snippet_links": [{"key": "first-contract-year", "type": "definition", "offset": [19, 38]}, {"key": "following-the-closing-date", "type": "clause", "offset": [39, 65]}, {"key": "net-sales", "type": "clause", "offset": [67, 76]}, {"key": "subsequent-contract", "type": "definition", "offset": [115, 134]}, {"key": "the-earn", "type": "definition", "offset": [147, 155]}, {"key": "out-period", "type": "definition", "offset": [156, 166]}, {"key": "prior-contract", "type": "clause", "offset": [260, 274]}], "size": 1, "snippet": "means:\n(a) For the first Contract Year following the Closing Date, Net Sales in excess of $2,400,000.\n(b) For each subsequent Contract Year during the Earn-Out Period, NetSales in excess of the greater of (1) $2,400,000 or (2) the highest Net Sales during any prior Contract Year during the Earn-Out Period.", "samples": [{"hash": "clwIVnaLaQh", "uri": "/contracts/clwIVnaLaQh#incremental-net-sales", "label": "Stock Purchase Agreement (Advanced Photonix Inc)", "score": 18.0, "published": true}], "hash": "bd8b50c35037b785f19fa01744265d43", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIeaW5jcmVtZW50YWwtbmV0LXNhbGVzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 28, "title": "Incremental Net Sales", "snippet": "for a particular period means that portion of the Net Sales (as defined below) of each of the Products sold by MEC or any of its Affiliates to KO/MEC Distributors during each calendar year (prorated for any period less than a calendar year) that exceeds the Base Volume during such calendar year (prorated for any period less than a calendar year) (i.e. the excess only).", "id": "incremental-net-sales", "examples": ["The Commission will be payable monthly in arrears within forty-five (45) days of the end of each month commencing the Effective Date based on MEC\u2019s good faith estimate of <strong>Incremental Net Sales</strong>, and shall be reconciled to reflect actual <strong>Incremental Net Sales</strong> for each calendar quarter within sixty (60) days of the end of such calendar quarter.", "Within ninety (90) days after the end of each Contract Year, Wyeth shall report to Impax the amount of Net Sales for each Product for which there were <strong>Incremental Net Sales</strong> during such Contract Year, the amount of <strong>Incremental Net Sales</strong> for each such Product for such Contract Year and the basis for Wyeth\u2019s calculation thereof.", "Together with such report, Wyeth shall pay to Impax an amount equal to XXXXX percent (XXXXX%) of each such Product\u2019s <strong>Incremental Net Sales</strong> (the \u201cIncentive Fee\u201d) for such Contract Year.", "The rejecting Party will pay to the Proposing Party, pursuant to Section 10.14(b)(vii) and (viii), [***] percent ([***]%) of <strong>Incremental Net Sales</strong> of such Alliance Product until the Proposing Party has recovered [***] percent ([***]%) of the Proposing Party\u2019s Development Costs for such Alliance Product, including any feasibility costs where an NPCD-Feasibility was rejected by the other Party.", "In the case of any Product that is Detailed under this Agreement for only a portion of a Contract Year (a \u201cPartial Contract Year\u201d), <strong>Incremental Net Sales</strong> shall be determined by reference to such Partial Contract Year by determining the following on the basis of such Partial Contract Year rather than the full Contract Year: XXXXX.", "<strong>Incremental Net Sales</strong> and the Net Profit thereon on a Region-by-Region basis, and shall be reconciled to reflect actual <strong>Incremental Net Sales</strong> and the Net Profit thereon for each calendar quarter within sixty (60) days of the end of such calendar quarter.", "If MEC\u2019s then-current Gross Profit Margin on any particular Product or package is: (a) more than *** percent *** then the Commissions on such Product or package will be *** percent *** of <strong>Incremental Net Sales</strong>; (b) less than *** percent *** but more than *** percent ***, then the Commission on such Product or package will be *** percent *** of <strong>Incremental Net Sales</strong>; or (c) *** percent *** or less, then the Commission on such Product or package will be *** percent *** of <strong>Incremental Net Sales</strong>.", "The incremental increase in prescriptions for XXXXX obtained from Targeted Neurologists above the general increase therefore results in <strong>Incremental Net Sales</strong> of $XXXXX (XXXXX * $XXXXX).", "Acura\u2019s receipt of the Gross Margin payment described above (\u201cCo-Promotion Payment\u201d) will be in lieu of the royalty payments otherwise payable to Acura under the Agreement calculated based on <strong>Incremental Net Sales</strong> resulting from prescriptions written by the health care providers contained in Acura\u2019s list provided to Egalet pursuant to Section 5.3.13.", "The GSK Marketing Expenses, determined quarterly, but not the Base Auxilium Marketing Expenses, shall be subtracted from the <strong>Incremental Net Sales</strong> amount before calculating each quarterly Promotional Payment due to GSK."], "related": [["incremental-term-facility", "Incremental Term Facility", "Incremental Term Facility"], ["incremental-term-loans", "Incremental Term Loans", "Incremental Term Loans"], ["incremental-term-loan", "Incremental Term Loan", "Incremental Term Loan"], ["incremental-term-a-loans", "Incremental Term A Loans", "Incremental Term A Loans"], ["incremental-revolving-increase", "Incremental Revolving Increase", "Incremental Revolving Increase"]], "related_snippets": [], "updated": "2025-07-06T21:58:41+00:00"}, "json": true, "cursor": ""}}